Loading...
Market
Main competitive advantage of orforglipron by end of 2026
2
Resolution / Starting Odds
Convenience • 25%
Cost • 25%
Efficacy • 25%
Other advantage • 25%
Industry reports, expert analysis, and consumer surveys
Story
Eli Lilly Anticipates Approval for Orforglipron Weight-Loss Pill in Early 2026
Jan 13, 2025, 06:07 PM
Eli Lilly & Co. is anticipating regulatory approval for its experimental weight-loss pill, orforglipron, as early as early 2026, according to CEO Dave Ricks. Ricks, speaking at the JPMorgan Healthcare Conference in San Francisco, indicated that data on the pill is expected by mid-2025. He highlighted that the oral form of the drug would be more convenient for patients and easier to manufacture at a large scale compared to the company's current injectable weight-loss drugs, which have faced supply shortages due to production constraints.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Eli Lilly • 25%
Other • 25%
Viking Therapeutics • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
None • 25%
European Union • 25%
United States • 25%
China • 25%
None • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
None • 25%
CTO • 25%
CEO • 25%
CFO • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Mathematical Reasoning • 25%
Computational Efficiency • 25%
Cost-effectiveness • 25%
Multitask Language Understanding • 25%
20% to 40% • 25%
More than 60% • 25%
41% to 60% • 25%
Less than 20% • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Focus on internal development • 25%
Other strategic move • 25%
Partnership with another biotech • 25%
Another acquisition in oncology • 25%
Multiple acquisitions completed • 25%
No acquisitions completed • 25%
Successful acquisition of another biotech • 25%
Successful acquisition of Sage Therapeutics • 25%